Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Novo Nordisk A/S

In a report released on May 22, David Evans from Kepler Capital maintained a Hold rating on Novo Nordisk, with a price target of DKK290.00. The com...

Kepler Capital  Keeps Their Hold Rating on Novo Nordisk (0QIU)

Novo Nordisk ( ($NVO) ) just unveiled an announcement. Novo Nordisk said on 22 May 2026 that the European Medicines Agency’s Committee for Medicina...

Novo Nordisk Wins EMA Panel Backing for First Oral Wegovy Obesity Pill in EU

The latest update is out from Novo Nordisk ( ($NVO) ). On May 22, 2026, Novo Nordisk announced that the European Medicines Agency’s Committee for M...

Novo Nordisk Wins CHMP Backing for High-Dose Wegovy Single-Dose Pen in EU

Novo Nordisk ($NVO) announced an update on their ongoing clinical study. Novo Nordisk is running a phase 3 study called AMAZE 3 to test a new weekl...

Novo Nordisk Expands Obesity Reach With AMAZE 3 Sleep Apnoea Trial

Deutsche Bank analyst Emmanuel Papadakis maintained a Hold rating on Novo Nordisk today and set a price target of DKK290.00. Papadakis covers the H...

Deutsche Bank  Remains a Hold on Novo Nordisk (0QIU)

Novo Nordisk ($NVO) announced an update on their ongoing clinical study. Novo Nordisk A/S has launched a Phase 1 trial titled “Bioequivalence Study...

Novo Nordisk Advances New Cagrilintide Study in the Race for Obesity Leadership

Novo Nordisk ($NVO) announced an update on their ongoing clinical study. AMAZE 2 is a Phase 3 study run by Novo Nordisk A/S to test a new weekly sh...

Novo Nordisk’s AMAZE 2 Trial: A New Weight-Loss Shot Targets Growth Beyond Semaglutide

Novo Nordisk ($NVO) announced an update on their ongoing clinical study. AMAZE 12 is a Phase 3 trial run by Novo Nordisk A/S that tests a new weekl...

Novo Nordisk’s AMAZE 12 Trial: Next Wave in Obesity Maintenance Drugs

In a report released today, James Gordon CFA from Barclays maintained a Hold rating on Novo Nordisk, with a price target of DKK300.00. According to...

Barclays Keeps Their Hold Rating on Novo Nordisk (0QIU)

Shares in drugmakers Pfizer ($PFE), Eli Lilly ($LLY), and Novo Nordisk ($NVO) edged lower on Monday afternoon after CNBC’s Megan Cassella revealed ...

PFE, NVO, LLY: Pharma Stocks Drop as TrumpRx Set for ‘Dramatic Expansion’

Hims & Hers ($HIMS) shares fell 8.5% on Monday after the company said it plans to raise $300 million through a private offering of convertible seni...

Here’s Why Hims & Hers Stock Tumbled 9% Today, 5/18/26

Eli Lilly ($LLY) has become the face of the global obesity drug boom, powered by its GLP-1 (glucagon-like peptide-1) based tirzepatide franchises M...

Eli Lilly (LLY) Is the Face of the Obesity Boom. Has the Market Already Priced It In?

Novo Nordisk ($NVO) announced an update on their ongoing clinical study. The study “A Study Investigating the Effect of Cagrilintide on Energy Inta...

Novo Nordisk’s Cagrilintide Trial Signals Next Wave in Obesity Treatment

Novo Nordisk ($NVO) announced an update on their ongoing clinical study. The AMAZE 6 trial, officially titled “Efficacy and Safety of NNC0487-0111 ...

Novo Nordisk Expands Obesity Pipeline With AMAZE 6 Knee Osteoarthritis Trial

Hims & Hers Health ($HIMS) stock was down about 11% on Tuesday, as of writing, after the telehealth company reported a larger-than-anticipated loss...

Hims & Hers Health Stock (HIMS) Sinks on Dismal Q1 Earnings and Outlook; Here’s What Analysts Are Saying

BMO Capital analyst Evan Seigerman maintained a Hold rating on Novo Nordisk today and set a price target of $45.00. According to TipRanks, Seigerma...

BMO Capital Remains a Hold on Novo Nordisk (NVO)

Traders looking for the top stock market stories on Friday are in the right palce.


Morning News Wrap-Up, 5/8/26: Today’s Biggest Stock Market Stories!

DZ BANK AG analyst Elmar Kraus maintained a Hold rating on Novo Nordisk yesterday. The company’s shares closed last Wednesday at DKK295.50. Accordi...

Novo Nordisk (0QIU) Gets a Hold from DZ BANK AG

Traders will find all of the latest earnings, analysts, and economic news in our daily wrap-up.


Morning News Wrap-Up, 5/7/26: Today’s Biggest Stock Market Stories!

Barclays Reaffirms Their Hold Rating on Novo Nordisk (0QIU)

Amazon ($AMZN) is adding Novo Nordisk ($NVO)’s Ozempic pill to Amazon Pharmacy, as it builds a deeper role in the fast-growing market for GLP-1 dru...

Amazon (AMZN) Targets GLP-1 Growth with Novo’s Ozempic Pill

Hims & Hers Health ($HIMS) will report its Q1 2026 earnings on May 11. The telehealth company heads into earnings with strong recent momentum, with...

HIMS Stock Forecast — What Financial Analysts Expect Ahead of Q1 Earnings

Earnings reports, analysts updates, and new peace talks have the stock market moving on Wednesday.


Morning News Wrap-Up, 5/6/26: Today’s Biggest Stock Market Stories!

Goldman Sachs analyst James Quigley maintained a Hold rating on Novo Nordisk today and set a price target of DKK263.00. According to TipRanks, Quig...

Novo Nordisk (0QIU) Receives a Hold from Goldman Sachs

Novo Nordisk ($NVO), maker of the popular weight-loss drug Wegovy, saw its shares move higher on Wednesday after reporting stronger-than-expected f...

Novo Nordisk Earnings: NVO Stock Rises as Wegovy Sales Drive Massive Q1 Beat

Novo Nordisk ($NVO) announced an update on their ongoing clinical study. Novo Nordisk (NVO) has updated a key Phase 3 trial on its obesity drug com...

Novo Nordisk Completes Key CagriSema Obesity Study, Raising the Stakes in the Weight-Loss Drug Race

Novo Nordisk ( ($NVO) ) has shared an update. Novo Nordisk has completed the first leg of its 12‑month share repurchase programme, which is part of...

Novo Nordisk Concludes First DKK 3.8bn Tranche of 2026 Share Buyback

Last week, stocks held near highs as gains in tech helped offset mixed macro news. The S&P 500 ($SPY) rose 0.29% to 7,230, while the Nasdaq (NDX) g...

The Week That Was, The Week Ahead: Macro and Markets, May 3

Shares in weight-loss drug maker Novo Nordisk ($NVO) climbed today after a study showed a link between the treatment and people battling alcoholism...

Novo Nordisk Stock (NVO) Rises after Study Shows Weight-Loss Drugs Can Help Alcoholics

Traders will find the top stock market stories for Friday in our daily wrap-up.


Morning News Wrap-Up, 5/1/26: Today’s Biggest Stock Market Stories!

Traders will find the most recent earnings reports, analysts updates, and economic data at TipRanks.


Morning News Wrap-Up, 4/30/26: Today’s Biggest Stock Market Stories!

Shares in drugmakers Eli Lilly ($LLY) and Novo Nordisk ($NVO) climbed on Thursday morning after the U.S. health watchdog proposed not to allow outs...

Eli Lilly, Novo Nordisk Stocks Jump as FDA Moves Against Bulk Production of Obesity Drug Ingredients

Cheaper generic obesity drugs are expected to compete against name brand versions.  


Eli Lilly Stock (LLY) Falls as Canada Approves Generic Weight-Loss Drugs

Novo Nordisk ( ($NVO) ) has issued an update. Novo Nordisk, a Danish-based global healthcare group specialising in treatments for serious chronic d...

Market Cap	$197.71B	P/E Ratio	12.77
52W High	$81.44	52W Low	$35.12
Div Yield	255.0%	Payout Ratio	42.4%
EPS Growth 3Y	0.0%	52W Position	19.6%
Overall Score	66	Value Score	90
Quality Score	50	Technical Score	58

EPS Current Est	$3.46	EPS Next Est	$3.44
EPS Growth Est	-0.6%	DPS Growth 3Y	0.0%

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NVO	$44.19	-1.71%	9.29M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	NVO	$44.19	-1.7%	9.29M
3
4
5
6

NVO

NVO

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Novo Nordisk A/S Data in Excel

Get Novo Nordisk A/S Data in Excel